Who owns ProQR Therapeutics N.V., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Van Herk Investments B.V.: 10.9% · 15,384,250 shares — Van Herk Investments THI B.V.: 10.9% · 15,384,250 shares — Van Herk Private Equity Investments B.V.: 10.9% · 15,384,250 shares
Aberdeen Group plc: 6.3% · 8,932,507 shares — abrdn Inc.: 6.3% · 8,932,507 shares
3 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of ProQR Therapeutics N.V..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of ProQR Therapeutics N.V. they hold. Together these 85 managers report 59.58% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $16.8M | 9,015,897 | 0.02% | 8.56% | June 30, 2026 |
| Aberdeen Group plc | $16.6M | 8,932,507 | 0.02% | 8.48% | June 30, 2026 |
83 more institutional holders behind a free account
See every manager reporting ProQR Therapeutics N.V., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 4 funds hold 0.05% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Invesco NASDAQ Future Gen 200 ETF | $44.9K | 0.32% | 0.03% | February 28, 2026 |
| TIFF MULTI-ASSET FUND | $41.2K | 0.00% | 0.02% | June 30, 2026 |
2 more funds behind a free account
See every fund holding ProQR Therapeutics N.V. and what share of its net assets the position represents.
Sign up freeLoading...
